Early‐onset colorectal cancer in young individuals
Treatment of young adults with colorectal cancer (CRC) represents an unmet clinical need,
especially as diagnosis in this population might lead to the greatest loss of years of life …
especially as diagnosis in this population might lead to the greatest loss of years of life …
The current state of molecular testing in the treatment of patients with solid tumors, 2019
The world of molecular profiling has undergone revolutionary changes over the last few
years as knowledge, technology, and even standard clinical practice have evolved. Broad …
years as knowledge, technology, and even standard clinical practice have evolved. Broad …
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …
a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial …
BRAF-mutated colorectal cancer: clinical and molecular insights
F Caputo, C Santini, C Bardasi, K Cerma… - International journal of …, 2019 - mdpi.com
Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity in the world.
It is a heterogeneous disease, which can be classified into different subtypes, characterized …
It is a heterogeneous disease, which can be classified into different subtypes, characterized …
Molecular targeted therapy of BRAF-mutant colorectal cancer
M Ducreux, A Chamseddine… - … in medical oncology, 2019 - journals.sagepub.com
Over the past two decades, the molecular characterization of metastatic colorectal cancer
(mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As …
(mCRC) has been revolutionized by the routine implementation of RAS and BRAF tests. As …
[HTML][HTML] Context matters—consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials
E Fontana, K Eason, A Cervantes, R Salazar… - Annals of …, 2019 - Elsevier
Abstract The Colorectal Cancer Subtyping Consortium identified four gene expression
consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and …
consensus molecular subtypes, CMS1 (immune), CMS2 (canonical), CMS3 (metabolic), and …
KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer–practical implications for the clinician
VA Afrăsânie, MV Marinca, T Alexa-Stratulat… - Radiology and …, 2019 - sciendo.com
Methods A search algorithm (Figure 1) based on a combination of the terms ''metastatic
colorectal cancer''AND “therapy” OR “treatment” AND “RAS” OR “KRAS” OR “NRAS” AND …
colorectal cancer''AND “therapy” OR “treatment” AND “RAS” OR “KRAS” OR “NRAS” AND …
The evolving biomarker landscape for treatment selection in metastatic colorectal cancer
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to
important improvements in patient outcomes. However, it is still necessary to increase …
important improvements in patient outcomes. However, it is still necessary to increase …
[HTML][HTML] A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool'study
Background Despite the well-known negative prognostic value of the V600E BRAF mutation
in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous …
in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous …
Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes
DS Williams, D Mouradov, RN Jorissen, MR Newman… - Gut, 2019 - gut.bmj.com
Objective Tumour-infiltrating lymphocyte (TIL) response and deficient DNA mismatch repair
(dMMR) are determinants of prognosis in colorectal cancer. Although highly correlated …
(dMMR) are determinants of prognosis in colorectal cancer. Although highly correlated …